TEMPO
Tempo, a leader in productivity-enhancing project management solutions, announces that Gary Jackson has been appointed as CEO, inheriting the role of CEO from Agust Einarsson.
Commenting on the transition which is effective April 2nd, Mr Einarsson said “I am proud of all that we have achieved over the past 12 years to build Tempo from a simple proprietary solution for time tracking, to a rapidly expanding software business with revenues of $22 million and global clients. After more than a decade serving in this leadership capacity, it’s time to be handing over the baton and Gary brings a breadth of expertise that will be invaluable in the next phase of Tempo’s expansion. I wish him and the rest of the team every success going forward.”
Mr Jackson’s appointment brings 25 years of executive leadership roles in enterprise B2B software companies with a focus in the last 18 years on developer productivity products. His dedication to process improvement, and honest communication has resulted in consistent achievement of company goals across his portfolio of efforts.
“My passion is to discover strategic advantages in the market and recruit high performing teams,” commented Gary Jackson, “I am delighted to be joining Tempo, which is now one of the largest app vendors on the Atlassian marketplace with more than 12,000 customers in over 120 countries. I wish Agust well for his future.”
A seamless handover process will be completed over the next weeks, leaving a company in excellent standing and primed for growth both within and outside of the Atlassian ecosystem.
The board of Tempo offers its sincere thanks to Mr Einarsson for his dedication and successful service for Tempo, and is pleased to welcome Mr Jackson into the role.
###
About Tempo
Tempo’s mission is to empower the world's most productive teams. Every day it helps people achieve their potential as smart, efficient and productive team members by building the world’s most useful, effortless and valuable tools for time, resource and cost management.
With headquarters in Reykjavik, Iceland and a North American presence in Montreal, Canada, Tempo provides a user friendly, high performance software suite for time tracking, resource management and budgeting. Tempo enables organizations to plan, optimize, and manage resources, budget and track project costs, and track and report time for team efficiency. Tempo has over 12,000 customers worldwide, ranging from small startups to the largest global enterprises including Amazon, BMW, Pfizer, HomeAway, PayPal, Hulu, Dell, and Disney.
To learn more about Tempo, visit www.tempo.io
About Diversis Capital
Founded in 2013, Diversis Capital, LLC (“Diversis”) is a private equity firm that invests in lower and middle-market companies, targeting situations where it can add unique value in helping a company reach the next level. With a collaborative approach to investing, its operating partners and strategic advisors work alongside management teams to help build successful organizations positioned for long-term growth. The firm focuses on standalone deals, carve-outs, partnerships and special situations that require sharp financial acumen, creativity, collaboration and operational expertise to reach success. Diversis, which was founded by Managing Directors Ron Nayot and Kevin Ma, is currently in full acquisition mode with a goal of executing several transactions annually.
For more information, please visit www.diversiscapital.com
About Origo
Origo hf. (NASDAQ: ORIGO) is a long-established, publicly listed Nordic IT services and solutions provider with offices in Iceland and Sweden. For over two decades, Origo has been assisting its customers with technical leadership, through the supply of the best-available technology, applications development, systems integration, facilities management and expert business process consultancy. Origo corporate roots can be traced back to 1899 with the very inception of “office machines”.
Today, under the leadership of CEO Finnur Oddsson, Origo aims to be the technology partner of choice for businesses, from the smallest to the largest enterprises. With expertise in understanding and linking the needs of enterprise customers to competitive technology solutions, Origo uses its deep knowledge of mission-critical processes, hardware and application requirements, to focus on government and industries sectors with high support needs such as healthcare, financial services, logistics and aviation.
For more information, please visit www.origo.is
Additional Resources
Follow the Tempo blog: http://blog.tempo.io
Follow us on Twitter: http://twitter.com/tempohq
Become a fan on Facebook: http://facebook.com/tempohq
Follow us on LinkedIn: https://www.linkedin.com/company/TempoHQ
View source version on businesswire.com: https://www.businesswire.com/news/home/20190405005198/en/
Contact:
Media Contact Gary Jackson CEO gary.jackson@tempo.io +354 532 2000
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom